Century Therapeutics (IPSC) Stock Statistics & Valuation Metrics

Century Therapeutics has a market cap or net worth of $425.94M. The enterprise value is $186.88M.

Century Therapeutics has 179,722,750 shares outstanding. The number of shares has decreased by -2.65% in one year.

Century Therapeutics’s return on equity (ROE) is -0.06 and return on invested capital (ROIC) is -7.22%.

The current PE Ratio of Century Therapeutics is ―. Century Therapeutics’s PEG ratio is 0.10.

In the last 12 months, Century Therapeutics had revenue of 109.16M and earned -9.58M in profits. Earnings per share was -0.11.

In the last 12 months, operating cash flow was -103.88M and capital expenditures -829.00K, giving a free cash flow of -104.70M billion.

Century Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Century Therapeutics upcoming earnings date is May 20, 2026, Before Open (Confirmed).

Century Therapeutics as a current ratio of 5.97, with Debt / Equity ratio of 27.41%

In the past 12 months, Century Therapeutics has paid -68.00K in taxes.

Century Therapeutics EV to EBITDA ratio is -34.98, with an EV/FCF ratio of -0.65.

Century Therapeutics has $117.11M in cash and marketable securities with $43.56M in debt, giving a net cash position of $73.55M billion.

Gross margin is 90.95%, with operating margin of -13.78%, and net profit margin of -8.78%.

The average price target for Century Therapeutics is $5.30, which is 11.43% higher than the current price. The consensus rating is Strong Buy